OSCR

Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target.

Overview

Authors: Jian-Lei Kang1,2, Yu-Jie Xu3, Qi-Tai Zhao4, Bing Zhang5, Xin Xu2, Bo Yang1
  1. Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  2. Department of Neurosurgery, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
  3. Department of Oncology, Henan Provincial People’s Hospital, Zhengzhou, China
  4. Biotherapy Center and Cancer Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  5. Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
Journal: Oncology research, volume 34, issue 7, article 23
Dates: received 17 January 2026; accepted 20 April 2026; published online 16 June 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.32604/or.2026.079221 · PMID 42358823 · PMCID PMC13291989 · OpenAlex W7161267704
Open access: hybrid, a free copy (OpenAlex)
Categories: genetics / omics (modality), human (organism), mouse (organism), other condition (population), cellular / molecular (subfield)
Methods: Connectivity, Statistics, Smoothing, state filtering, decompositions, Machine learning, Preprocessing
Keywords: Glioma, heterogeneity, immunosuppressive tumor microenvironment, insulin-like growth factor binding protein 2
MeSH: Biomarkers, Tumor*, Brain Neoplasms*, Glioma*, Insulin-Like Growth Factor Binding Protein 2*, Animals, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Humans, Mice, Neoplasm Recurrence, Local, Prognosis, Single-Cell Analysis (* major topic)
Topic: Macrophage Migration Inhibitory Factor (Immunology, Immunology and Microbiology), according to OpenAlex
Citations: not cited yet (Europe PMC); 72 references in the paper

Abstract

Background: Glioma is among the most malignant brain tumors, and its heterogeneity contributes significantly to treatment failure. Comprehensive profiling of cellular and molecular heterogeneity across different glioma stages and recurrence states is crucial for understanding therapeutic resistance and identifying novel targets. Accordingly, this study sought to systematically characterize the cellular and molecular heterogeneity of glioma across different stages and recurrence states using single-cell RNA sequencing, and to identify prognostic subtypes and potential therapeutic targets. Methods: We integrated public single-cell RNA sequencing data from glioma specimens, including lower-grade glioma (LGG), glioblastoma (GBM), and paired primary and recurrent tumors. Using these datasets, we identified distinct cellular subpopulations and their molecular signatures. Based on these glioma cell subpopulations, we reclassified gliomas from The Cancer Genome Atlas (TCGA) database into molecular subtypes and constructed a prognostic model. The functional role of a key candidate gene, insulin-like growth factor binding protein 2 (IGFBP2), was validated using in vitro knockdown experiments in mouse and human tumor cells and in vivo therapeutic studies in murine models, including combination therapy with anti-programmed cell death protein 1 (anti-PD-1) immune checkpoint blockade. Results: This analysis revealed that T cells in GBM and recurrent samples were predominantly exhausted, characterized by upregulation of PD-1 and T-cell immunoglobulin and mucin-domain containing−3 (Tim3), while myeloid cells exhibited an immunosuppressive phenotype with elevated expression of macrophage migration inhibitory factor (MIF) and cluster of differentiation (CD)276. We identified 12 distinct glioma cell subpopulations with varying proliferative and hypoxic signatures. Based on these subpopulations, TCGA gliomas were reclassified into two major subtypes. One subtype, enriched with myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), was associated with poorer patient prognosis. A prognostic model was successfully established using differentially expressed genes between the subtypes. Furthermore, IGFBP2 was highly expressed in glioma cells, and its expression negatively correlated with T cell infiltration. In vitro knockdown of IGFBP2 downregulated programmed death-ligand 1 (PD-L1) expression on tumor cells. In vivo, IGFBP2 knockdown significantly suppressed tumor growth (p < 0.01) and extended survival in tumor-bearing mice (p < 0.05), and its combination with anti-PD-1 therapy markedly enhanced antitumor efficacy. Conclusions: This study provides deeper insights into the cellular ecosystem and heterogeneity of glioma, linking specific cellular features to patient prognosis. We identify IGFBP2 may play a role in regulating immunosuppressive tumor microenvironment and a potential therapeutic target.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Other data links

Availability of Data and Materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 6 authors, 4 keywords, 12 MeSH terms, 72 references.

Cite

This paper

Kang, J.-L., Xu, Y.-J., Zhao, Q.-T., Zhang, B., Xu, X., & Yang, B. (2026). Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target. Oncology research, 34(7), 23. https://doi.org/10.32604/or.2026.079221

BibTeX

@article{kang2026single,
author = {Kang, Jian-Lei and Xu, Yu-Jie and Zhao, Qi-Tai and Zhang, Bing and Xu, Xin and Yang, Bo},
title = {{Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target}},
journal = {Oncology research},
year = {2026},
month = jun,
volume = {34},
number = {7},
pages = {23},
publisher = {Tech Science Press},
issn = {0965-0407},
doi = {10.32604/or.2026.079221},
url = {https://doi.org/10.32604/or.2026.079221},
pmid = {42358823},
pmcid = {PMC13291989}
}

RIS

TY - JOUR
AU - Kang, Jian-Lei
AU - Xu, Yu-Jie
AU - Zhao, Qi-Tai
AU - Zhang, Bing
AU - Xu, Xin
AU - Yang, Bo
TI - Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target
T2 - Oncology research
J2 - Oncol Res
PY - 2026
DA - 2026/06/16
VL - 34
IS - 7
SP - 23
SN - 0965-0407
PB - Tech Science Press
DO - 10.32604/or.2026.079221
UR - https://doi.org/10.32604/or.2026.079221
LA - en
ER -

CSL-JSON

{
"id": "10.32604/or.2026.079221",
"type": "article-journal",
"title": "Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target",
"container-title": "Oncology research",
"author": [
{
"family": "Kang",
"given": "Jian-Lei"
},
{
"family": "Xu",
"given": "Yu-Jie"
},
{
"family": "Zhao",
"given": "Qi-Tai"
},
{
"family": "Zhang",
"given": "Bing"
},
{
"family": "Xu",
"given": "Xin"
},
{
"family": "Yang",
"given": "Bo"
}
],
"container-title-short": "Oncol Res",
"volume": "34",
"issue": "7",
"page": "23",
"DOI": "10.32604/or.2026.079221",
"PMID": "42358823",
"PMCID": "PMC13291989",
"ISSN": "0965-0407",
"publisher": "Tech Science Press",
"URL": "https://doi.org/10.32604/or.2026.079221",
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
16
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s41586-026-10612-6 [code]
Acquired genetic and cell-state changes in IDH-mutant glioma progression.
Journal: Nature
In common: other condition, cellular / molecular, 9 references
[2] doi:10.1038/s41467-025-58366-5 [code]
Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression.
Journal: Nature communications
In common: genetics / omics, other condition, mouse, 1 other category, 8 references
[3] doi:10.3390/cancers14194915 [code]
Transcriptome Analysis Identifies Accumulation of Natural Killer Cells with Enhanced Lymphotoxin-β Expression during Glioblastoma Progression.
Journal: Cancers
In common: genetics / omics, other condition, mouse, 1 other category, 8 references
[4] doi:10.3390/biom13060904
Gasdermin D Plays an Oncogenic Role in Glioma and Correlates to an Immunosuppressive Microenvironment.
Journal: Biomolecules
In common: NCBI GEO GSE138794, other condition, cellular / molecular, 5 references
[5] doi:10.1093/noajnl/vdad101
Dissecting the tumor microenvironment of epigenetically driven gliomas: Opportunities for single-cell and spatial multiomics.
Journal: Neuro-oncology advances
In common: genetics / omics, other condition, cellular / molecular, 8 references
[6] doi:10.1038/s41467-024-52167-y [code]
Glioblastoma cells increase expression of notch signaling and synaptic genes within infiltrated brain tissue.
Journal: Nature communications
In common: genetics / omics, other condition, cellular / molecular, 8 references
[7] doi:10.3389/fgene.2024.1356611 [code]
Cellular diversity through space and time: adding new dimensions to GBM therapeutic development.
Journal: Frontiers in genetics
In common: genetics / omics, other condition, cellular / molecular, 8 references
[8] doi:10.1038/s41423-025-01360-0
C/EBPβ-induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma.
Journal: Cellular & molecular immunology
In common: other condition, mouse, cellular / molecular, 8 references
[9] doi:10.1093/noajnl/vdad142 [code]
Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains.
Journal: Neuro-oncology advances
In common: genetics / omics, other condition, cellular / molecular, 8 references
[10] doi:10.1186/s40478-023-01613-x
Decoding key cell sub-populations and molecular alterations in glioblastoma at recurrence by single-cell analysis.
Journal: Acta neuropathologica communications
In common: genetics / omics, other condition, cellular / molecular, 8 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.